感染疾病的共同研究·授权契约(2019年～2025年)

本报告提供全球生物医药品产业调查分析，提供2019年～2025年的感染疾病的共同研究·授权契约1,786件相关，契约条件等详细资讯。

目录

摘要整理

第1章 简介

第2章 感染疾病契约趋势

• 简介
• 过去数年的感染疾病合作伙伴契约
• 感染疾病合作伙伴契约:各类型契约
• 感染疾病合作伙伴契约:各产品部门
• 感染疾病合作伙伴契约:各开发阶段
• 感染疾病合作伙伴契约:各技术类型
• 感染疾病合作伙伴契约:各适应症

第3章 感染疾病对策相关财务的契约条件

• 简介
• 感染疾病合作伙伴契约相关公开的财务条件
• 感染疾病合作伙伴契约的标题金额
• 感染疾病契约的预付款
• 感染疾病契约的阶段性付款
• 感染疾病的权利金费率

第4章 主要感染疾病契约与谈判者

• 简介
• 在感染疾病合作伙伴契约中最活跃
• 感染疾病领域的最活跃的谈判者的清单
• 前几名的感染疾病契约(金额)

第5章 感染疾病契约文件名录

• 简介
• 合同可取得的感染疾病合作伙伴契约

第6章 按感染疾病契约:治疗标的

• 简介
• 契约:感染疾病治疗标的
• 契约名录
• 契约名录 - 感染疾病契约:各企业(A～Z)(2019年～2025年)
• 契约名录 - 感染疾病契约:各技术类型(2019年～2025年)
• 契约类型定义
• 关于Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Current Partnering的近几年报告的标题

Infectious Diseases Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the infectious diseases deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of 1,786 infectious diseases deals from 2019 to 2025.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of infectious diseases dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in infectious diseases dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the infectious diseases field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in infectious diseases dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of infectious diseases deals signed and announced since 2019 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of infectious diseases deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in infectious diseases deal making since 2019.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Infectious Diseases Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2019
• Browse infectious diseases collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Infectious Diseases Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of infectious diseases trends and structure of deals entered into by leading biopharma companies worldwide.

Infectious Diseases Collaboration and Licensing Deals includes:

• Trends in infectious diseases dealmaking in the biopharma industry
• Overview of collaboration and licensing deal structure
• Directory of infectious diseases deal records covering pharmaceutical and biotechnology
• The leading infectious diseases deals by value
• Most active infectious diseases licensing dealmakers

In Infectious Diseases Collaboration and Licensing Deals, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Infectious Diseases Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in infectious diseases dealmaking

• 2.1. Introduction
• 2.2. Infectious diseases partnering over the years
• 2.3. Infectious diseases partnering by deal type
• 2.4. Infectious diseases partnering by industry sector
• 2.5. Infectious diseases partnering by stage of development
• 2.6. Infectious diseases partnering by technology type
• 2.7. Infectious diseases partnering by therapeutic indication

Chapter 3 - Financial deal terms for infectious diseases partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for infectious diseases partnering
• 3.3. Infectious diseases partnering headline values
• 3.4. Infectious diseases deal upfront payments
• 3.5. Infectious diseases deal milestone payments
• 3.6. Infectious diseases royalty rates

Chapter 4 - Leading infectious diseases deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in infectious diseases partnering
• 4.3. List of most active dealmakers in infectious diseases
• 4.4. Top infectious diseases deals by value

Chapter 5 - Infectious diseases contract document directory

• 5.1. Introduction
• 5.2. Infectious diseases partnering deals where contract document available

Chapter 6 - Infectious diseases dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by infectious diseases therapeutic target
• Deal directory
• Deal directory - Infectious diseases deals by company A-Z 2019 to 2025
• Deal directory - Infectious diseases deals by technology type 2019 to 2025
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Infectious diseases partnering since 2019
• Figure 2: Infectious diseases partnering by deal type since 2019
• Figure 3: Infectious diseases partnering by industry sector since 2019
• Figure 4: Infectious diseases partnering by stage of development since 2019
• Figure 5: Infectious diseases partnering by technology type since 2019
• Figure 6: Infectious diseases partnering by indication since 2019
• Figure 7: Infectious diseases deals with a headline value
• Figure 8: Infectious diseases deals with upfront payment values
• Figure 9: Infectious diseases deals with milestone payment
• Figure 10: Infectious diseases deals with royalty rates
• Figure 11: Active infectious diseases dealmaking activity since 2019
• Figure 12: Top infectious diseases deals by value since 2019